UnknownNot Applicable

Early Diagnosis and Prognosis of Postoperative Sepsis by Presepsin and Syndecan-1

30 participantsStarted 2021-02

Plain-language summary

The aim of the present work is to study: Persepsin (sCD-14) and Syndecan-1 as biomarkers following major surgeries for early diagnosis and prognosis of sepsis Primary aim: early diagnosis and prognosis of sepsis Secondary aim: correlate them with SOFA and qSOFA scores.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Patients aged \<18 years old.
✕. Patients with terminal stage of malignancy of any type.
✕. Immune-compromised patients e.g., on immune-suppressive therapy, acquired immunodeficiency syndrome
✕. Patients with end-stage liver or renal disease.
✕. Patients with existing infection before surgery.
✕. Patients with emergency surgeries.
✕. Pregnancy.
✕. Chronic inflammatory disorders e.g., sarcoidosis

What they're measuring

Evaluate Presepsin (sCD-14) and Syndecan-1 as biomarkers following major surgeries for early diagnosis and prognosis of sepsis

Timeframe: baseline

Trial details

NCT IDNCT04718623

SponsorAlexandria University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-03

Contact for this trial

HOSSAM A HASSAN

+201026100724 drhossam@gmail.com

View on ClinicalTrials.gov More Sepsis Following A Procedure trials